A Phase 1, first-in-human, multicenter, open-label, dose-escalation, and multi-cohort expansion study designed to evaluate INBRX-109 in patients with locally advanced or metastatic solid tumors, including sarcomas.

Contact Information for Access

• sandra.aliberti@inoc.it
• francesco.tolomeo@inoc.it
• nicolo.gariglio@inoc.it

Status

ATTIVO

---

Objective of the study

1. To evaluate the safety and tolerability of intravenously administered INBRX-109 (IV) in combination with various chemotherapies in adults and/or adolescents with advanced/metastatic Ewing sarcoma and solid tumors with succinate dehydrogenase (SDH) deficiency or gastrointestinal stromal tumors (GIST).

2. To evaluate the antitumor efficacy of INBRX-109 administered intravenously (IV) in combination with irinotecan and temozolomide (TMZ) in Ewing sarcoma based on the objective response rate (ORR) and duration of response (DOR).

Multiple Indications: Ewing sarcoma, colorectal adenocarcinoma, GISTs, and tumors with succinate dehydrogenase deficiency.

ClinicalTrials.gov ID NCT03715933
Sponsor: Inhibrx Biosciences, Inc

https://euclinicaltrials.eu/search-for-clinical-trials/?lang=en&EUCT=2023-508139-29-00

Medication

INBRX-109 (anti-TRAIL DR5 antibody).

Who is eligible to participate in the study?

Patients who are 18 years of age or older and who meet the study’s eligibility criteria may participate in this study.
Patients who have received at least 1 and no more than 2 prior treatments.

View the full study Back to search page